NCT02572453: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL |
|
|
| Terminated | 2 | 25 | US | Onalespib, AT 13387, AT-13387, AT13387 | National Cancer Institute (NCI) | Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma | 03/21 | 03/21 | | |
